HLS Therapeutics Inc (HLS) Fair Value & Analysis
Healthcare · CA · Market cap C$140M
Fair value as of: Jun 24, 2026
From 12 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from C$4.19 to C$6.85 (+63.5%) since Jun 23, 2026. Share price −3.9% over the past month.
Price vs Fair Value (12 months)
12‑month range C$4.15 – C$5.73 · fair‑value band C$4.83 – C$8.87 · the C$4.42 price screens below the C$6.85 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
HLS Therapeutics Inc (HLS) currently trades at C$4.42, while our model-based Fair Value estimate is C$6.85 — implying the stock looks roughly 55.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, HLS Therapeutics Inc generated revenue of C$55.7M at a net margin of -18.5%. Revenue grew 1.9% year over year. It earns a return on equity of -16.4%. Net debt stands at C$38.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, arip…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
HLS Therapeutics Inc reported revenue of C$56.5M in FY2025 versus C$60.0M in FY2021, a compound −1.5%/yr. Reported net income was −C$12.6M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is HLS Therapeutics Inc (HLS) undervalued?
What is the fair value of HLS?
What is the quality score of HLS?
What is the revenue of HLS Therapeutics Inc (HLS)?
What is the net profit margin of HLS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.